Green Leaf Pharmaceutical: LY01005 Chinese III phase III clinical trials that treat breast cancer reached the preset end

On July 24, 2022, Green Leaf Pharmaceutical (02186.HK), a listed company of Hong Kong stocks, announced that the Chinese III clinical trials of mammary cancer (LY01005) for the treatment of mammary gosharin -gosherelin for injection reached the preset end point.

According to the announcement, the phase III clinical is a random, open, and positive drug control clinical study. It adopts non -inferior test design. Compared with the control drugs, the effectiveness and safety of the LY01005 continuous muscle injection to the treatment of patients with breast cancer treat patients with breast cancer. Essence

Based on the results of clinical research, for patients with breast cancer, LY01005 injects breast cancer every 28 days of muscle injection at 3.6 mg doses, which can effectively control serum estradiol to postmenopausal levels. Essence LY01005 is similar to the safety characteristics of the control drug, and research shows that LY01005 has no adverse reactions without injection, patient compliance increases, and the overall clinical safety tolerance is good.

LY01005 is a most -release micro -ball -made agent developed by the group using its own micro -ball technology platform to use muscle injection once a month. As far as the company knows, the only dosage form that Gosherin has been listed at present is subcutaneous implants. Through innovative microsphere technology, LY01005 can effectively reduce adverse reactions in the injection site, improve patients with medication, reduce the difficulty of nursing, and enhance the patient's tolerance and compliance. It is more conducive to the treatment of drugs and has obvious clinical advantages.

At present, the LY01005 China listing license application based on prostate cancer indications is under review and approval. At the same time, the group will also apply for the newly used clinical results of the breast cancer III in this product based on the completion of this product.

The company said that LY01005 solves the current clinical needs, provides new treatment options for patients with prostate and breast cancer, and benefits more patients. At the same time, this product has good market potential in China. It is expected to form a wealth of product portfolio with the Group's anti -tumor products, and cooperates with the Group's existing resources and advantages in the tumor field to accelerate the company's layout and development in this field.

- END -